Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prevention is better than cure: the case for clinical trials of therapeutic cancer vaccines in the prophylactic setting.

Literature DB >> 20729485

Prevention is better than cure: the case for clinical trials of therapeutic cancer vaccines in the prophylactic setting.

Andrew Gray¹, Lisa Yan, W Martin Kast.

Abstract

Entities: Disease

Mesh：

Substances：
Cancer Vaccines

Year: 2010 PMID： 20729485 PMCID： PMC2965609 DOI： 10.1124/mi.10.4.2

Source DB: PubMed Journal: Mol Interv ISSN： 1534-0384

× No keyword cloud information.

20 in total

1. Prostate cancer immunotherapy yields superior long-term survival in TRAMP mice when administered at an early stage of carcinogenesis prior to the establishment of tumor-associated immunosuppression at later stages.

Authors: Andrew Gray; Maria de la Luz Garcia-Hernandez; Myrna van West; Shreya Kanodia; Bolyn Hubby; W Martin Kast
Journal: Vaccine Date: 2009-12-30 Impact factor: 3.641

Review 2. Chemoprevention of prostate cancer.

Authors: Ian M Thompson; Catherine M Tangen; Phyllis J Goodman; M Scott Lucia; Eric A Klein
Journal: J Urol Date: 2009-06-13 Impact factor: 7.450

Review 3. Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors: Weiping Zou
Journal: Nat Rev Cancer Date: 2005-04 Impact factor: 60.716

4. An autoimmune-mediated strategy for prophylactic breast cancer vaccination.

Authors: Ritika Jaini; Pavani Kesaraju; Justin M Johnson; Cengiz Z Altuntas; Daniel Jane-Wit; Vincent K Tuohy
Journal: Nat Med Date: 2010-05-30 Impact factor: 53.440

Review 5. HER2/neu as a predictive factor in breast cancer.

Authors: C Lohrisch; M Piccart
Journal: Clin Breast Cancer Date: 2001-07 Impact factor: 3.225

Review 6. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.

Authors: Andrew Gray; Adam B Raff; Maurizio Chiriva-Internati; Si-Yi Chen; W Martin Kast
Journal: Immunol Rev Date: 2008-04 Impact factor: 12.988

7. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model.

Authors: Paula J Kaplan-Lefko; Tsuey-Ming Chen; Michael M Ittmann; Roberto J Barrios; Gustavo E Ayala; Wendy J Huss; Lisette A Maddison; Barbara A Foster; Norman M Greenberg
Journal: Prostate Date: 2003-05-15 Impact factor: 4.104

8. The influence of finasteride on the development of prostate cancer.

Authors: Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal: N Engl J Med Date: 2003-06-24 Impact factor: 91.245

9. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

Authors: Philip W Kantoff; Thomas J Schuetz; Brent A Blumenstein; L Michael Glode; David L Bilhartz; Michael Wyand; Kelledy Manson; Dennis L Panicali; Reiner Laus; Jeffrey Schlom; William L Dahut; Philip M Arlen; James L Gulley; Wayne R Godfrey
Journal: J Clin Oncol Date: 2010-01-25 Impact factor: 44.544